Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab in Japanese patients with advanced STS or solid tumors
NCT02377752Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaratumab in soft tissue sarcoma (STS) and solid tumor (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With One or More Serious Adverse Event(s) up To 3.5 Years, Number of Participants With Dose Limiting Toxicities and 2 more. Started Mar 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)solid tumor
Beyond the preview
Go deeper on NCT02377752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02377752.